Reaction
Gastrointestinal Bacterial Infection reporting signals
As of the last recalculation, Gastrointestinal Bacterial Infection appears in 1,128 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 22.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ado-Trastuzumab Emtansine | 10 | 22.1 | 22.1 |
| Vedolizumab | 80 | 18.4 | 18.4 |
| Telmisartan | 17 | 17.8 | 17.8 |
| Thiotepa | 9 | 17.5 | 17.5 |
| Travoprost | 8 | 17.2 | 17.2 |
| Lapatinib | 14 | 16.8 | 16.9 |
| Goserelin | 11 | 15.3 | 15.3 |
| Gentamicin | 10 | 14.2 | 14.2 |
| Infliximab-Dyyb | 20 | 12.8 | 12.8 |
| Rifaximin | 13 | 11.6 | 11.6 |
| Teduglutide | 8 | 11.0 | 11.0 |
| Desoximetasone | 11 | 10.7 | 10.8 |
| Busulfan | 9 | 10.6 | 10.6 |
| Fentanyl Citrate | 10 | 10.4 | 10.4 |
| Pertuzumab | 11 | 7.5 | 7.5 |
| Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride | 12 | 7.2 | 7.2 |
| Ustekinumab | 34 | 6.3 | 6.3 |